Epidemiology and comorbidities of patients with chronic urticaria in Korea: A nationwide population‐based study

Kim, Bo Ri; Yang, Seungkeol; Choi, Jee Woong; Choi, Chong Won; Youn, Sang Woong

doi:10.1111/1346-8138.14075

Cited by 62 publications

(59 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, in accordance with the literature, 71.3% of CU patients were female and their mean age was 41.9. In a study conducted by Kim et al, urticaria-associated comorbidities such as allergic rhinitis, drug allergy, asthma, thyroid disease, and cancer were found [10]. In this study, 6.1% (n = 11) of the cases had thyroid pathology.…”

Section: Discussionsupporting

confidence: 41%

Omalizumab usage in chronic urticaria and atopic dermatitis: data from South-East province of Turkey

Nazik¹,

Mülayim²,

Öztürk³

2019

pdia

View full text Add to dashboard Cite

A b s t r a c tIntroduction: Omalizumab is a current treatment option for IgE-associated dermatoses, such as urticaria and atopic dermatitis. Aim: To evaluate the clinical and laboratory findings of patients with chronic urticaria and atopic dermatitis who received omalizumab. Material and methods: This study was planned as a cross-sectional and retrospective one. One hundred forty-six cases were included in the study. Omalizumab at a dose of 300 mg for patients with chronic urticaria and 600 mg for patients with atopic dermatitis, was given every 4 weeks. The response to the given treatment and remission status of patients were investigated. Results: Of 146 patients included in the study, 70.5% (n = 103) were female and their mean age was 42.3 ±13.8 (min.-max.: 14-85). Of the patients, 136 had chronic urticaria and 10 had atopic dermatitis. 29.9% (n = 26) of patients with chronic urticaria had a complete response to omalizumab treatment, whereas 40% (n = 4) of patients with atopic dermatitis had remission. Conclusions: The decline of complaints with different treatment schemes in different patients suggests that treatment should be designed individually and that personal biomarkers playing a role in the effectiveness of the drug are important. Patients with the high IgE and eosinophil percentages and positive autologous serum test had a better treatment response to omalizumab treatment. Meanwhile, remission was found to be more frequent in atopic dermatitis patients with omalizumab treatment compared to the patients with urticaria. It may be more appropriate to choose patients based on certain criteria to ensure cost-effectiveness in omalizumab treatment.

show abstract

Section: Discussionsupporting

confidence: 41%

Omalizumab usage in chronic urticaria and atopic dermatitis: data from South-East province of Turkey

Nazik¹,

Mülayim²,

Öztürk³

2019

pdia

View full text Add to dashboard Cite

show abstract

“…21 This result is consistent with previous studies both in Scandinavia and the rest of the world. 3,4,8 Our data suggest a higher prevalence and risk of autoimmune diseases, including rheumatoid arthritis, vitiligo, and thyroiditis among CU patients. However, they are very differently represented.…”

Section: Discussionmentioning

confidence: 61%

“…More women than men were diagnosed with CU, similar to observations in other studies. 3,4,15 It may reflect a gender dependent distribution of CU, but as our data are based on hospital registries, results may also reflect the fact that men are less likely to seek medical attention than women. 16 Consequently, we suggest that male cases of CU may need further information on the disease and on its treatments.…”

Section: Discussionmentioning

confidence: 96%

“…Recent data suggest that CU is not only a disease of the mast cells, it also is a systemic 3,4 autoimmune disease. 5 Furthermore, it has been shown that CU patients also have an increased risk of having other autoimmune conditions, which may be associated to urticaria or increase the patient's susceptibility to CU, 6 although the pathogenic mechanisms of CU have not been fully understood.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Risk of comorbidities in patients diagnosed with chronic urticaria: A nationwide registry-study

Ghazanfar¹,

Kibsgaard²,

Thomsen³

et al. 2020

World Allergy Organization Journal

View full text Add to dashboard Cite

Background: The autoimmune profile of Chronic Urticaria (CU) patients is an increasing topic of interest. Associated diseases suggest shared pathogenic pathways, and they may provide important knowledge on specific targets for future treatment models. In this study we examined the prevalence and risk of comorbidities in CU. Methods: The Danish National Patient Registry was used to identify all CU patients from 1994 to 2015. Five of 5 specialized dermatological units in Denmark were covered. Analyses were conducted as a nested case control study and a matched cohort study. CSU patients were matched 1:10 on age and sex to an otherwise random group of people from the background population. Results: A total of 12,185 CU patients were identified, with an overweight of female cases (69% versus 32%). There was an overrepresentation of mast cell mediated diseases including mastocytosis and anaphylaxis, as well as atopic diseases including type 1 allergies and atopic dermatitis. The prevalence of rheumatoid arthritis, systemic lupus erythematosus, thyroiditis and vitiligo was also increased, as was the prevalence of depression. CU patients who did not have any of the comorbidities at the time of their CU diagnosis had an increased risk of developing both mast cell mediated diseases, atopic diseases, and autoimmune diseases excluding thyroiditis and diabetes. Conclusion: The autoimmune profile of the comorbidities of CU was demonstrated with an evident risk of developing rheumatoid arthritis. CU patients were also at increased risk of either having or achieving depression. Mast cell related diseases seemed to be overrepresented, although registry data within this disease category are questionable and similar to symptoms of CU to the untrained eye. Thus, CU patients constitute a multimorbid group of patients, which must be recognized among treating physicians.

show abstract

“…Being a mast cell disease and potentially associated with a autoimmune disease, diagnoses of systemic autoimmune diseases and other mast cell disorders should be considered (39,40). Apparently, CU is associated with a speci c pattern of comorbidities, including autoimmune, atopic and psychiatric diseases and there is no clear pattern in relation to malignant and cardiovascular diseases (41).…”

Section: Discussionmentioning

confidence: 99%

Refractory Chronic Urticaria in Adults: Clinical Characterization and Predictors of Severity

Coutinho

Regateiro

Fernandes

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Chronic urticaria (CU) is defined as recurrent urticaria lasting for more than 6 weeks. Objectives: We aimed to characterize the phenotypes of patients with CU refractory to standard dose anti-H1 antihistamine treatment and search for clinical predictors of poor disease control.Methods: Retrospective collection of data regarding clinical characteristics, manifestations, comorbidities, treatment, and disease control of all adult refractory CU patients presenting to the Allergy and Immunology Department during one year. Descriptive and inferential analysis was performed to search for factors associated with disease control. Results: Sixty-one adult patients were included, 74% females, average age 44.5 years (18 to 84 years old). Most patients (78.7%) had initiated CU less than 1 year before enrolment. Chronic spontaneous urticaria (CSU) accounted for 55.7% of the patients and chronic inducible urticaria (ClndU) for 44.3%. Angioedema was present in 55.7% of the patients. Evidence for autoimmunity (positive anti-thyroid peroxidase antibodies, anti-nuclear antibodies or autologous serum test) was found in 45.2% (n=19) of 42 tested patients. High C-reactive protein was presenti in 14.3% (n=6) of 42 patients evaluated; half of these also had positive antinuclear antibodies. Forty-six patients (75.4%) had at least one significant exacerbation, requiring medical appointment, emergency room, hospitalization or job absenteeism. The number of exacerbations correlated with the presence of angioedema (p=0.022), with a recent diagnosis (<1 year), and with higher UAS7 severity (p=0.006). ClndU associated with poor symptom control (p=0.022) but had less exacerbations requiring medical observation or hospitalization (p=0.015). Conclusions: About half of the patients with CU presented autoimmunity. UAS7 severity and Angioedema are associated with disease exacebations. UAS7 and UCT presented unequal accuracy, with UAS7 better associating with the occurrence of exacerbations and treatment dosis. Accurate diagnostic tests, namely autoimmune parameters and inflammatory markers, should be recommended in some individual cases.

show abstract

Epidemiology and comorbidities of patients with chronic urticaria in Korea: A nationwide population‐based study

Cited by 62 publications

References 22 publications

Omalizumab usage in chronic urticaria and atopic dermatitis: data from South-East province of Turkey

Omalizumab usage in chronic urticaria and atopic dermatitis: data from South-East province of Turkey

Risk of comorbidities in patients diagnosed with chronic urticaria: A nationwide registry-study

Refractory Chronic Urticaria in Adults: Clinical Characterization and Predictors of Severity

Contact Info

Product

Resources

About